Pharmaceuticals company Mankind Pharma announced Q2FY24 & H1FY24 results: Q2FY24: Revenue from Operations at Rs 2,708 crore, up by 12% YoY Domestic revenue at Rs 2,529 crore, up by 7% YoY Export revenue at Rs 179 crore, up by 159% YoY EBITDA at Rs 686 crore, up by 15% YoY with a margin of 25% PAT at Rs 511 crore, up by 21% YoY with a margin of 19% Cash flow from operations of Rs 481 crore Diluted EPS of Rs 12.5, up by 19% YoY (FV Re 1) H1FY24: Revenue from Operations at Rs 5,287 crore, up by 15% YoY Domestic revenue at Rs 4,948 crore, up by 10% YoY Export revenue at Rs 339 crore, up by 182% YoY EBITDA at Rs 1,346 crore, up by 28% YoY with a margin of 25% PAT at Rs 1,005 crore, up by 40% YoY with a margin of 19% Diluted EPS of Rs 24.6, up by 39% YoY (FV Re 1) CAPEX of Rs 225 crore Net cash balance of Rs 2,159 crore as on September 30, 2023 Rajeev Juneja, Vice Chairman & Managing Director, said, “ We continue to report steady performance with Revenue/ EBITDA and PAT growing by 12% / 15% and 21% YoY respectively. While the Pharma segment has grown at par with IPM (vs outperformance earlier) – due to delayed acute season, we expect to outperform IPM given strong chronic growth and uptick in season. Focus on increasing our chronic share led to the outperformance of 1.4x versus IPM Chronic growth in H1FY24. The past strategic choices in various aspects of our business are showing success, and we are confident in our ability to consistently surpass the industry growth in the future.” Result PDF
Conference Call with Mankind Pharma Management and Analysts on Q1FY24 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Mankind Pharma announced Q1FY24 results: Revenue from operations at Rs 2,579 crore, up by 18% YoY EBITDA at Rs 660 crore, up by 43% YoY with a margin of 25.6% PAT at Rs 494 crore, up by 66% YoY with a margin of 19.2% EPS of Rs 12.1, up by 66% YoY (FV Rs 1) CAPEX of Rs 111 crore Rajeev Juneja – Vice-Chairman & Managing Director, said, “We have started the year on a healthy note, with strong double-digit growth in sales and profitability. The Pharma segment outperformed the IPM by 1.5X led by volume-led growth and highest ever chronic share. Our consumer healthcare segment maintained dominant brand leadership in respective categories. We have also seen positive results from our prior initiatives to improve profitability, with EBITDA growing 43% YoY. Our market disruptive “DMF Quality Products” campaign has seen an outstanding response and we are rapidly expanding our product offerings in this important initiative. Our strategic initiatives across the businesses are delivering positive results and we are hopeful that we will continue to outperform industry growth, going ahead." Result PDF
Conference Call with Mankind Pharma Management and Analysts on Q4FY23 Performance and Outlook. Listen to the full earnings transcript.